ziprasidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 43 Diseases   13 Trials   13 Trials   784 News 


«123456789101112»
  • ||||||||||  Journal:  Ziprasidone in the treatment of bipolar disorder with comorbid obsessive-compulsive disorder and gambling disorder. (Pubmed Central) -  Apr 23, 2020   
    Comorbid OCD in BD is associated with younger age of onset, greater risk of suicide, rapid cycling (3) or more progressively depressive episodes, more severe impairment in social function, and poorer response to treatment, including pharmacologic (hypo) manic switch, lower lithium responsiveness, and exacerbation of OCD symptoms by neuroleptic agents...Recently, risperidone, quetiapine, olanzapine, and aripiprazole have been reported to be effective in the treatment of BD with OCD as an add-on therapy (4), suggesting atypical antipsychotics might play a role in the treatment of BD with comorbid OCD...Therefore, here we introduce a case of BD with comorbid OCD and GD, who was successfully treated with ziprasidone. These data contribute to the knowledge concerning available treatment options for these kinds of patients.
  • ||||||||||  risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
    Trial completion date, Trial suspension, Trial primary completion date:  Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) -  Mar 24, 2020   
    P1,  N=25, Suspended, 
    Additionally, variable microbiome responses to resistant starch supplementation were seen, with a significant increase in starch degraders. Trial completion date: Mar 2020 --> Mar 2022 | Recruiting --> Suspended | Trial primary completion date: Mar 2020 --> Mar 2021
  • ||||||||||  Journal:  Current Evidences on Psychopharmacology of Schizoaffective Disorder. (Pubmed Central) -  Mar 22, 2020   
    Likewise, there is evidence from observational studies showing the usefulness of lithium and carbamazepine during the treatment maintenance phase. It is necessary to establish the role of combined treatment with mood stabilizers and/or antidepressants.
  • ||||||||||  aripiprazole / Generic mfg., Latuda (lurasidone oral) / Sumitomo Dainippon, ziprasidone / Generic mfg.
    [VIRTUAL] TRENDS IN ATYPICAL ANTIPSYCHOTIC MEDICATION USE IN US ADULTS () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_288;    
    The results of this study can be used to inform prescribing behavior, clinical decision-making processes, and to predictively model future trends in atypical antipsychotic use. Further research should be conducted to assess the trends in institutionalized populations within the US as these patients have a higher risk of atypical antipsychotic exposure.
  • ||||||||||  Journal:  Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression. (Pubmed Central) -  Feb 27, 2020   
    Appropriate atypical antipsychotic included aripiprazole, clozapine, or quetiapine...However, patients who were taking levodopa (OR=0.62, 95% CI: 0.57-0.67), dopamine agonists (OR=0.90, 95% CI: 0.82-0.98), Catechol-O-methyltransferase (COMT) inhibitors (OR=0.77, 95% CI: 0.68-0.86), Monoamine Oxidase (MAO) inhibitors type B (OR=0.72, 95% CI: 0.60-0.86), or amantadine (OR=0.84, 95% CI: 0.71-0.98) were less likely to receive inappropriate antipsychotics...Various socio-demographics and clinical factors were associated with inappropriate antipsychotic use in older patients with PD. Concerted efforts are needed to reduce inappropriate atypical antipsychotic use among PD patients.
  • ||||||||||  sertraline / Generic mfg., ziprasidone / Generic mfg.
    Phase classification:  Ziprasidone and Sertraline in PTSD (clinicaltrials.gov) -  Feb 25, 2020   
    P=N/A,  N=7, Terminated, 
    No abstract available Phase classification: P2 --> P=N/A
  • ||||||||||  Belviq (lorcaserin) / Eisai
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Gene-by-Stress Interactions in Intervention Studies Significance (clinicaltrials.gov) -  Feb 17, 2020   
    P1,  N=7, Terminated, 
    Metabolic changes varied more among the SGAs. N=100 --> 7 | Trial completion date: Nov 2022 --> Jan 2020 | Enrolling by invitation --> Terminated | Trial primary completion date: Nov 2021 --> Jan 2020; Lack of participants
  • ||||||||||  olanzapine / Generic mfg., ziprasidone / Generic mfg., clozapine / Generic mfg.
    Ziprasidone Induced Diabetic Ketoacidosis (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_3057;    
    Clozapine and olanzapine are the common atypical antipsychotics that can cause DKA 1, 2...There is hypothesis regarding leptin gene polymorphisms of receptors that may play a role 4 . While starting patients on Ziprasidone, close monitoring of blood glucose is necessary before initiation and regular follow up thereafter 3 .
  • ||||||||||  Saphris (asenapine) / Allergan, Lundbeck, Meiji Seika, olanzapine / Generic mfg., Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
    Clinical, Journal:  Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents (Pubmed Central) -  Feb 3, 2020   
    Ziprasidone and asenapine are less effective in treating schizophrenia in children and adolescents than other antipsychotics. Compared to adults, children and adolescents are at higher risk of metabolic impairments when taking antipsychotics.
  • ||||||||||  Journal:  A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. (Pubmed Central) -  Jan 18, 2020   
    The compiled serum concentrations and the C/D ratios can support the physician's decision when individualizing dosing and determining treatment strategies for a specific patient.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
  • ||||||||||  7% Weight Change Associated With Antipsychotics: A Meta-Analysis (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_936;    
    Olanzapine (29.5%) and lurasidone (7.4%) resulted in respectively the highest and lowest CRWG at >38 weeks of treatment...CRWL occurred with all antipsychotic drugs; at 6-16 weeks aripiprazole (7.9%) and ziprasidone (7.1%) had CRWL similar to placebo (8.7%)...More future research is needed on long-term weight effects on both CRWG and CRWL to give a clear overview on the ‘real’ effects on weight, as the majority of studies had a duration of less than 26 weeks. Furthermore, more research is needed on the long-term dose-response relationship in CRWG, as this could prove to be a method for managing weight in some patients.
  • ||||||||||  Treatment Strategies for Ultra-Resistant Schizophrenias (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_934;    
    Electroconvulsive therapy seems to be the only non-pharmacological technique with enough data to support its efficacy in ultra-resistant cases of schizophrenia. Other neuromodulatory techniques, like tDCS, are still in early phase of investigation, and psychotherapy does not have enough evidence to support its efficacy.
  • ||||||||||  Disease Prevalence, Comorbid Conditions, and Medication Utilization among Patients with Schizophrenia in the United States (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_531;    
    Discussion This large-scale database analysis confirmed the burden of medical and psychiatric comorbidities in patients with schizophrenia compared with controls and provided additional insight on treatment approaches in these patients. Understanding the comorbidities affecting this patient population in comparison with the general population highlights the importance of integrated medical and psychiatric care.
  • ||||||||||  Antipsychotics Result in Weight Gain but the Severity of Weight Gain Differs between Antipsychotics. (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_73;    
    Other AP result in modest weight gain to weight loss over the various time periods: amisulpride (range -0.76 and 1.40), aripriprazole (range -0.81 and 0.81), asenapine (-0.99 – 1.14), haloperidol (0.49 – 1.31) and ziprasidone (-1.18 – -0.38)...Given only patient older than 17years were included, this might explain the limited number of available studies. However, younger age seems to be associated were an increased risk of weight gain.
  • ||||||||||  Clinical, Review, Journal:  Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence. (Pubmed Central) -  Jan 1, 2020   
    Clinical trials evaluating the efficacy of different treatment options have been conducted but they are extremely heterogenous and most have numerous methodological flaws, leading to a poor overall quality of evidence upon which guidelines for the appropriate treatment could be based. The combination of haloperidol and promethazine, which combines the sedative properties of the antihistamine with the more selective calming action of haloperidol (with a reduced risk of extrapyramidal effects compared to haloperidol alone because of the anticholinergic properties of promethazine) may be the best choice based on empirical evidence.
  • ||||||||||  Clinical, Journal:  Hospitalization Risk in Bipolar Disorder Patients Treated with Lurasidone versus Other Atypical Antipsychotics. (Pubmed Central) -  Jan 1, 2020   
    In this claims database analysis, lurasidone-treated patients with bipolar disorder had a significantly lower risk of psychiatric hospitalization compared to quetiapine, olanzapine, and risperidone, but not aripiprazole or ziprasidone. Lurasidone-treated patients had a significantly lower risk of all-cause hospitalization compared to quetiapine, olanzapine, risperidone, and aripiprazole, but not ziprasidone.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  PTN_POPS: Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (clinicaltrials.gov) -  Dec 12, 2019   
    P=N/A,  N=3520, Completed, 
    Complementary in vivo studies could be useful to confirm these in vitro findings described here. Recruiting --> Completed | N=10000 --> 3520 | Trial completion date: Feb 2020 --> Nov 2019 | Trial primary completion date: Feb 2020 --> Nov 2019
  • ||||||||||  olanzapine / Generic Mfg., quetiapine / Generic Mfg., Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
    Clinical, Journal:  Deprescribing in a Youth with an Intellectual Disability, Autism, Behavioural Problems, and Medication-Related Obesity: A Case Study. (Pubmed Central) -  Dec 8, 2019   
    Vlad's case may typify important deficiencies in the service system which create a context that allows for aggressive psychotropic polypharmacy without apparent concomitant increase in sophistication of behavioral management design and support, while also tolerating substantial treatment adverse effects (e.g., medication induced severe obesity) within a member of a vulnerable population (e.g., a youth with developmental disability in care). Suggestions to address some of these contextual factors are outlined.
  • ||||||||||  Biomarker, Journal:  Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing. (Pubmed Central) -  Nov 23, 2019   
    What was common among those drugs almost always in the green bin versus those almost never in the green bin were newer versus older marketed drugs and those not dependent versus dependent on oxidative metabolism for their clearance. The authors concluded that the results of this pharmacogenetic testing could be predicted on the basis of knowledge of the pharmacology of the drugs, particularly whether their clearance was dependent on oxidative drug metabolism.
  • ||||||||||  Clinical, PK/PD data, Review, Journal:  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. (Pubmed Central) -  Nov 2, 2019   
    This review concentrates on the clinical pharmacokinetic data related to clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, sertindole, asenapine, iloperidone, lurasidone, brexpiprazole and cariprazine and briefly considers the main aspects of their pharmacodynamics. Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine, amisulpride, asenapine, iloperidone and lurasidone provide only limited information and there is no direct evidence concerning ziprasidone, aripiprazole, sertindole, brexpiprazole and cariprazine: the few reported investigations need to be confirmed and extended.
  • ||||||||||  Real-World Effectiveness of Antipsychotic Treatments in 37,368 Patients With Schizophrenia in the U.S. VA System (Floridian Ballroom) -  Oct 17, 2019 - Abstract #ACNP2019ACNP_1135;    
    These results show clearly that clozapine, long-acting injectable second generation antipsychotics and antipsychotic polypharmacy are taken for the longest period by patients and might be considered to be the most effective drugs in this study; oral antipsychotics were less effective then oral olanzapine in terms of time to discontinuation. These results are strikingly similar to those of very similar studies performed in Scandinavia and reflect what happens in clinical practice, but contradict guidelines recommending monotherapy.